Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
Vermeire S, Schreiber S, Rubin DT, D'Haens G, Reinisch W, Watanabe M, Mehta R, Roblin X, Beales I, Gietka P, Hibi T, Hospodarskyy I, Ritter T, Genovese MC, Kwon P, Santermans E, Le Brun FO, Barron R, Masior T, Danese S.
Vermeire S, et al. Among authors: kwon p.
Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00272-3. doi: 10.1016/S2468-1253(24)00272-3. Online ahead of print.
Lancet Gastroenterol Hepatol. 2024.
PMID: 39637881
Free article.